D. Boral Capital Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 137.19% from the stock’s current price.

URGN has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Stock Up 1.6 %

Shares of NASDAQ URGN opened at $10.54 on Wednesday. UroGen Pharma has a 12-month low of $9.78 and a 12-month high of $20.70. The company has a market cap of $247.16 million, a P/E ratio of -3.35 and a beta of 1.08. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock has a fifty day moving average price of $10.88 and a 200 day moving average price of $12.39.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Large investors have recently bought and sold shares of the business. Barclays PLC raised its holdings in shares of UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after buying an additional 48,040 shares during the last quarter. Wesbanco Bank Inc. bought a new stake in shares of UroGen Pharma during the third quarter valued at approximately $945,000. JPMorgan Chase & Co. raised its holdings in shares of UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after buying an additional 49,318 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after buying an additional 34,248 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of UroGen Pharma during the third quarter valued at approximately $5,080,000. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.